Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in advanced medullary thyroid carcinoma
NCT01736878Phase 2Withdrawn
- Sponsor
- EANM Research
- Start
- Oct 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in medullary thyroid carcinoma (MTC), sponsored by EANM Research. Planned start Oct 2012; status: withdrawn.
02
Drugs
sorafenib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT01736878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736878.